<DOC>
	<DOCNO>NCT01658839</DOCNO>
	<brief_summary>The purpose study assess safety describe steady-state plasma pharmacokinetic ( PK ) profile Travoprost ophthalmic solution , 0.004 % ( new formulation ) follow daily administration 7 day pediatric glaucoma ocular hypertension patient .</brief_summary>
	<brief_title>Pharmacokinetic Safety Study Travoprost 0.004 % Pediatric Glaucoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis glaucoma ocular hypertension least 1 eye . Parent/legal guardian must provide informed consent , child must agree sign approve assent form applicable . Must agree comply requirement study must accompany parent/guardian . Other protocoldefined inclusion criterion may apply . Females childbearing potential currently pregnant , positive result pregnancy test Screening Visit , intend become pregnant study period , breast feeding , use birth control measure . One sight eye monocular , include patient dosed eye reason . History chronic , recurrent severe inflammatory eye disease . Ocular trauma require medical attention within past 3 month prior Screening Visit . Ocular infection ocular inflammation within past 30 day prior Screening Visit . Clinically significant progressive retinal disease retinal degeneration , diabetic retinopathy , retinal detachment . Other severe ocular pathology ( include severe dry eye ) , opinion Investigator , would preclude administration topical prostaglandin analogue . Intraocular surgery within past 30 day prior Screening Visit . Any abnormality prevent reliable tonometry . Any condition include severe illness would make patient , opinion Investigator , unsuitable study . Hypersensitivity prostaglandin analogue component study medication opinion Investigator . Therapy another investigational agent device within 30 day prior Screening Visit . Body weight &lt; 5kg . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>pediatric glaucoma</keyword>
	<keyword>pediatric ocular hypertension</keyword>
	<keyword>travoprost</keyword>
</DOC>